Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 2, 2011, Pages 79-85

  Nosadini, R ^a   Tonolo, G ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b SC Aziendale di Diabetologia e Malattie Metaboliche   (Italy)

Author keywords

Albumin excretion rate; CD36; Glomerular filtration rate; Oxidized low density lipoproteins; Scavenger receptors

Indexed keywords

FATTY ACID; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

CYTOLOGY; DIABETIC NEPHROPATHY; FOAM CELL; HUMAN; INTERSTITIAL NEPHRITIS; LIPID METABOLISM; MACROPHAGE; MESANGIUM; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATION REDUCTION REACTION; PATHOLOGY; PODOCYTE; REVIEW;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FATTY ACIDS, NONESTERIFIED; FOAM CELLS; GLOMERULAR MESANGIUM; HUMANS; LIPID METABOLISM; LIPOPROTEINS, LDL; MACROPHAGES; NEPHRITIS, INTERSTITIAL; OBESITY; OXIDATION-REDUCTION; PODOCYTES;

EID: 79451472114     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.10.002     Document Type: Review

References (42)

1. Hopps E., Noto D., Calmi G., Averna M.R. A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis 2010, 20:72-77.
2. Fioretto P., Mauer M., Brocco E., Velussi M., Frigato F., Muollo B., et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996, 39:1569-1576.
3. Nosadini R., Velussi M., Brocco E., Bruseghin M., Abaterusso C., Saller A., et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 2000, 49:476-484.
4. Mauer S.M., Steffes M.W., Ellis E.N., Sutherland D.E., Brown D.M., Goetz F.C. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984, 74:1143-1155.
5. Osterby R., Parving H.-H., Hommel E., Jorgensen H.E., Lokkegaard H. Glomerular structure and function in diabetic nephropathy. Early to advanced stages. Diabetes 1990, 39:1057-1063.
6. Abrass C.K. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 2004, 24:46-53.
7. Kean W.F. The role of lipids in renal disease. Future challenges. Kidney Int 2003, 57:527-531.
8. Santini E., Lupi R., Baldi S., Madec S., Cimenti D., Ferrannini E., et al. Effects of different LDL particles on inflammatory molecules in human mesangial cells. Diabetolgia 2008, 51:2117-2125.
9. Nosadini R., Velussi M., Brocco E., Abaterusso C., Piarulli F., Morgia G., et al. Altered transcapillary escape of albumin and microalbuminuria reflect two different pathogenetic mechanisms. Diabetes 2005, 54:228-233.
10. Nosadini R., Velussi M., Brocco E., Abaterusso C., Piarulli F., Morgia G., et al. Increased renal arterial resistance predicts the course of renal function in type 2 diabetes with microalbuminuria. Diabetes 2006, 55:234-239.
11. Masulli M., Mancini M., Liuzzi R., Daniele S., Mainenti P., Vergara E., et al. Measurement of the intrarenal arterial resistance index for the Identification and prediction of diabetic nephropathy. Nutr Metab Cardiovasc Dis 2009, 19:358-364.
12. Retnakaran R., Cull C.A., Thome K.I., Adler A.I., Holman R.R. Risk factors for renal dysfunction in type 2 diabetes: UK 74. Diabetes 2006, 55:1832-1839. UKPDS Group.
13. MacIsaac R.J., Panagiotopoulos S., McNeil K.J., Smith T.J., Tsalamandris C., Hao H., et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?. Diabetes Care 2006, 29:1560-1566.
14. Rossi M.C.E., Nicolucci A., Pellegrini F., Comaschi M., Cervello A., Cucinotta D., et al. Obesity and changes in urine albumin/creatinine ratio in patients with type 2 diabetes 2: the DEMAND Study. Nutr Metab Cardiovasc Dis 2010, 20:110-116.
15. Svensson M., Sundkvist G., Arnqvist H.J., Björk E., Blohmé G., Bolinder J., et al. Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population based Diabetes Incidente Study in Sweden (DISS). Diabetes Care 2003, 26:2903-2909. Diabetes Incidence Study in Sweden (DISS).
16. Meyer C., Gerich J.E. Role of the kidney in hyperglycemia in type 2 diabetes. Curr Diab Rep 2002, 2:237-241.
17. Wang Z., Jiang T., Li J., Proctor G., McManam J.L., Lucia S., et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 2005, 54:2328-2335.
18. Woerle H.J., Popa E., Dostou J., Welle S., Gerich J., Meyer C. Exogenous insulin replacement in type 2 diabetes reverses excessive hepatic glucose release, but not excessive renal glucose release and impaired free fatty acid clearance. Metabolism 2002, 51:1494-1500.
19. Park Y.M., Febraio M., Silverstein R.L. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contributo to macrophage trapping in the arterial intima. J Clin Invest 2009, 119:136-145.
20. Tryggvason K., Patrakka J., Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 2006, 354:1387-1401.
21. Ruotsalainen V., Kjunbberg P., Wartiovaara J., Lenkeri U., Kestil M., Jalanko H., et al. Nephrin is specifically located at slit diaphragm of glomerular podocytes. Proc Natl Acad Sci USA 1999, 96:796-967.
22. Pagtulanan M.E., Miller P.L., Jumping-Eagle S., Nelson R.G., Myers B.D., Renne H.G., et al. Podocyte loss and progressive glomerular injury in type 2 diabetes. J Clin Invest 1997, 99:342-348.
23. Bussolati B., Deregibus M.C., Fonsato V., Doublier S., Spatola T., Procida S., et al. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT signaling pathway. J Am Soc Nephrol 2005, 16:1936-1947.
24. Agarwal A., Balla J., Balla G., Croatt A.J., Vercellotti G.M., Nath K. Renal tubular epithelial cells mimic endothelial cells upon exposure to oxidized LDL. Am J Physiol 1996, 271:F814-F823.
25. Gutwein P., Abdel-Bakky M.S., Schramme A., Doberstein K., Kämpfer-Kolb N., Amann K., et al. CXCL16 is expressed in podocytes and acts as scavenger receptor for oxidized low-density pipoprotein. J Am J Pathol 2009, 174:2061-2072.
26. Tonolo G., Velussi M., Brocco E., Abaterusso C., Carraro A., Morgia G., et al. Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int 2006, 70:177-186.
27. Schrauwen P., Hesselink M.K. Oxidative capacità, lipotoxicity and mitochondrial damage in type 2 diabetes. Diabetes 2004, 53. p. 1412-1075.
28. Gutwein P., Abdel-Bakky M.S., Doberstein K., Schramme A., Beckmann J., Schaefer L., et al. CXCL16 and ox-LDL are induced in the onset of diabetic nephropathy. J Cell Mol Med 2009 Sep, 13(9B):3809-3825.
29. Sayyed S., Hagele H., Kulkarni O., Endlich K., Segerer S., Eulbrg D., et al. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerusclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 2009 Nov, 52(11):2445-2454.
30. Anders H.J., Vielhauer V., Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal diseases. Kidney Int 2003, 63:401-415.
31. Lee T.M., Su S.F., Tsai C.H. Effect of pravastatin on proteinuria in patients with well controlled hypertension. Hypertension 2002, 40:67-73.
32. Nakamura T., Ushiyama C., Hirokawa K., Osada S., Inone T., Stimata N., et al. Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 2002, 17:798-802.
33. Mayrhofer C., Krieger S., Huttary N., Chang M.W., Grillari J., Allmaier G., et al. Alterations in fatty acid utilization and an impaired antioxidant defense mechanism are early events in podocyte injury. A proteomic analysis. Am J Pathol 2009, 174:1191-1202.
34. Sun L., Hailaihel N., Zhang W., Rogers T., Levi M. Role of sterol regulatory element binding protein -1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 2002, 277:18919-18927.
35. Lennon R., Pons D., Sabin M.A., Wei C., Shield J.P., Coward R.J., et al. Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy. Nephrol Dial Transplant 2009, 24:3288-3296.
36. Coward R.J., Welsh G.I., Yang J. The human glomerular podocyte is a novel target for insulin action. Diabetes 2005, 54:3095-3102.
37. Coward R.J., Welsh G.I., Koziell A. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes 2007, 56:1127-1135.
38. Palmen T., Ahola H., Palgi J., Aaltonen P., Luimula P., Wang S., et al. Nephrin is expressed in the pancreatic beta cells. Diabetologia 2001, 44:1274-1280.
39. Fornoni A., Jean J., Santos J.V., Cobianchi L., Jaregui A., Inverardi L., et al. Nephrin is expressed on the surface of insulin vesicles and facilitates glucose stimulated insulin release. Diabetes 2009 Oct 28, [Epub ahead of print].
40. Bakris G.L., Ruilope L.M., McMorn S.O. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006, 24:2047-2055.
41. Nakamura T., Ushiyama C., Osada S. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001, 50:1193-1196.
42. Ritz E., Rychlik I., Locatelli F., Salimi S. End stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999, 34:794-808.